In arrayed ranks array technology in the study of mesothelioma steven
2009-01-01 Gray, S. G.; Fennell, D. A.; Mutti, L.; O'Byrne, K. J.
SV40 and human brain tumors [2]
2003-01-01 Carbone, M.; Bocchetta, M.; Cristaudo, A.; Emri, S.; Gazdar, A.; Jasani, B.; Lednicky, J.; Miele, L.; Mutti, L.; Pass, H. I.; Ramael, M.; Rizzo, P.; Testa, J. R.; Weggen, S.; Yeung, A.
Will antiangiogenic agents be a future for mesothelioma therapy?
2010-01-01 Belli, C.; Anand, S.; Panella, M.; Giovannini, M.; Tassi, G.; Fennell, D.; Mutti, L.
Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications
2002-01-01 Sigalotti, L.; Coral, S.; Altomonte, M.; Natali, L.; Gaudino, G.; Cacciotti, P.; Libener, R.; Colizzi, F.; Vianale, G.; Martini, F.; Tognon, M.; Jungbluth, A.; Cebon, J.; Maraskovsky, E.; Mutti, L.; Maio, M.
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma
2012-01-01 Blayney, J. K.; Ceresoli, G. L.; Castagneto, B.; O'Brien, M. E. R.; Hasan, B.; Sylvester, R.; Rudd, R.; Steele, J.; Busacca, S.; Porta, C.; Mutti, L.; O'Byrne, K. J.; Scullin, P.; Gaafar, R.; Baas, P.; Van Meerbeeck, J.; Fennell, D. A.
What can independent research for mesothelioma achieve to treat this orphan disease?
2019-01-01 Guazzelli, A.; Meysami, P.; Bakker, E.; Bonanni, E.; Demonacos, C.; Krstic-Demonacos, M.; Mutti, L.
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
2010-01-01 Scherpereel, A.; Astoul, P.; Baas, P.; Berghmans, T.; Clayson, H.; De Vuyst, P.; Dienemann, H.; Galateau-Salle, F.; Hennequin, C.; Hillerdal, G.; Le Pechoux, C.; Mutti, L.; Pairon, J. -C.; Stahel, R.; Van Houtte, P.; Van Meerbeeck, J.; Waller, D.; Weder, W.
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients
2005-01-01 Porta, C.; Zimatore, M.; Bonomi, L.; Imarisio, I.; Paglino, C.; Sartore-Bianchi, A.; Mutti, L.
Simian Virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey
2000-01-01 Emri, S.; Kocagoz, T.; Olut, A.; Gungen, Y.; Mutti, L.; Baris, Y. I.
MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications
2010-01-01 Busacca, S.; Germano, S.; De Cecco, L.; Rinaldi, M.; Comoglio, F.; Favero, F.; Murer, B.; Mutti, L.; Pierotti, M.; Gaudino, G.
HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy
2020-01-01 Correale, Pierpaolo; Mutti, Luciano; Pentimalli, Francesca; Baglio, Giovanni; Emilena Saladino, Rita; Sileri, Pierpaolo; Giordano, Antonio
{CONFIRM} trial: what is the real efficacy of second-line immunotherapy in mesothelioma?
2022-01-01 Correale, Pierpaolo; Pentimalli, Francesca; Nardone, Valerio; Giordano, Antonio; Mutti, Luciano
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
2020-01-01 Correale, P.; Saladino, R. E.; Giannarelli, D.; Sergi, A.; Mazzei, M. A.; Bianco, G.; Giannicola, R.; Iuliano, E.; Forte, I. M.; Calandruccio, N. D.; Falzea, A. C.; Strangio, A.; Nardone, V.; Pastina, P.; Tini, P.; Luce, A.; Caraglia, M.; Caracciolo, D.; Mutti, L.; Tassone, P.; Pirtoli, L.; Giordano, A.; Tagliaferri, P.
Association of SV40 with human tumours
2001-01-01 Jasani, B.; Cristaudo, A.; Emri, S. A.; Gazdar, A. F.; Gibbs, A.; Krynska, B.; Miller, C.; Mutti, L.; Radu, C.; Tognon, M.; Procopio, A.
Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor
2008-01-01 Ugolini, D.; Neri, M.; Ceppi, M.; Cesario, A.; Dianzani, I.; Filiberti, R.; Gemignani, F.; Landi, S.; Magnani, C.; Mutti, L.; Puntoni, R.; Bonassi, S.
Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group
2005-01-01 Porta, C.; Ardizzoni, A.; Gaudino, G.; Maio, M.; Mutti, L.; Pinto, C.; Porru, S.; Puntoni, R.; Tassi, G.; Tognon, M.
Recurrent chromosome 6 abnormalities in malignant mesothelioma
1998-01-01 Mutti, L.
In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors
1995-01-01 Stacchini, A.; Fubini, L.; Gatti, E.; Mutti, L.; Piacibello, W.; Sanavio, F.; Scagliotti, G.; Pozzi, E.; Aglietta, M.
Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma
2009-01-01 Aceto, N.; Bertino, P.; Barbone, D.; Tassi, G.; Manzo, L.; Porta, C.; Mutti, L.; Gaudino, G.
New agents in the management of advanced mesothelioma
2005-01-01 Vogelzang, N. J.; Porta, C.; Mutti, L.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| In arrayed ranks array technology in the study of mesothelioma steven | 1-gen-2009 | Gray, S. G.; Fennell, D. A.; Mutti, L.; O'Byrne, K. J. | |
| SV40 and human brain tumors [2] | 1-gen-2003 | Carbone, M.; Bocchetta, M.; Cristaudo, A.; Emri, S.; Gazdar, A.; Jasani, B.; Lednicky, J.; Miele, L.; Mutti, L.; Pass, H. I.; Ramael, M.; Rizzo, P.; Testa, J. R.; Weggen, S.; Yeung, A. | |
| Will antiangiogenic agents be a future for mesothelioma therapy? | 1-gen-2010 | Belli, C.; Anand, S.; Panella, M.; Giovannini, M.; Tassi, G.; Fennell, D.; Mutti, L. | |
| Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications | 1-gen-2002 | Sigalotti, L.; Coral, S.; Altomonte, M.; Natali, L.; Gaudino, G.; Cacciotti, P.; Libener, R.; Colizzi, F.; Vianale, G.; Martini, F.; Tognon, M.; Jungbluth, A.; Cebon, J.; Maraskovsky, E.; Mutti, L.; Maio, M. | |
| Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma | 1-gen-2012 | Blayney, J. K.; Ceresoli, G. L.; Castagneto, B.; O'Brien, M. E. R.; Hasan, B.; Sylvester, R.; Rudd, R.; Steele, J.; Busacca, S.; Porta, C.; Mutti, L.; O'Byrne, K. J.; Scullin, P.; Gaafar, R.; Baas, P.; Van Meerbeeck, J.; Fennell, D. A. | |
| What can independent research for mesothelioma achieve to treat this orphan disease? | 1-gen-2019 | Guazzelli, A.; Meysami, P.; Bakker, E.; Bonanni, E.; Demonacos, C.; Krstic-Demonacos, M.; Mutti, L. | |
| Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma | 1-gen-2010 | Scherpereel, A.; Astoul, P.; Baas, P.; Berghmans, T.; Clayson, H.; De Vuyst, P.; Dienemann, H.; Galateau-Salle, F.; Hennequin, C.; Hillerdal, G.; Le Pechoux, C.; Mutti, L.; Pairon, J. -C.; Stahel, R.; Van Houtte, P.; Van Meerbeeck, J.; Waller, D.; Weder, W. | |
| Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients | 1-gen-2005 | Porta, C.; Zimatore, M.; Bonomi, L.; Imarisio, I.; Paglino, C.; Sartore-Bianchi, A.; Mutti, L. | |
| Simian Virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey | 1-gen-2000 | Emri, S.; Kocagoz, T.; Olut, A.; Gungen, Y.; Mutti, L.; Baris, Y. I. | |
| MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications | 1-gen-2010 | Busacca, S.; Germano, S.; De Cecco, L.; Rinaldi, M.; Comoglio, F.; Favero, F.; Murer, B.; Mutti, L.; Pierotti, M.; Gaudino, G. | |
| HLA-B*44 and C*01 Prevalence Correlates with Covid19 Spreading across Italy | 1-gen-2020 | Correale, Pierpaolo; Mutti, Luciano; Pentimalli, Francesca; Baglio, Giovanni; Emilena Saladino, Rita; Sileri, Pierpaolo; Giordano, Antonio | |
| {CONFIRM} trial: what is the real efficacy of second-line immunotherapy in mesothelioma? | 1-gen-2022 | Correale, Pierpaolo; Pentimalli, Francesca; Nardone, Valerio; Giordano, Antonio; Mutti, Luciano | |
| HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis | 1-gen-2020 | Correale, P.; Saladino, R. E.; Giannarelli, D.; Sergi, A.; Mazzei, M. A.; Bianco, G.; Giannicola, R.; Iuliano, E.; Forte, I. M.; Calandruccio, N. D.; Falzea, A. C.; Strangio, A.; Nardone, V.; Pastina, P.; Tini, P.; Luce, A.; Caraglia, M.; Caracciolo, D.; Mutti, L.; Tassone, P.; Pirtoli, L.; Giordano, A.; Tagliaferri, P. | |
| Association of SV40 with human tumours | 1-gen-2001 | Jasani, B.; Cristaudo, A.; Emri, S. A.; Gazdar, A. F.; Gibbs, A.; Krynska, B.; Miller, C.; Mutti, L.; Radu, C.; Tognon, M.; Procopio, A. | |
| Genetic susceptibility to malignant mesothelioma and exposure to asbestos: The influence of the familial factor | 1-gen-2008 | Ugolini, D.; Neri, M.; Ceppi, M.; Cesario, A.; Dianzani, I.; Filiberti, R.; Gemignani, F.; Landi, S.; Magnani, C.; Mutti, L.; Puntoni, R.; Bonassi, S. | |
| Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VII th Meeting of the International Mesothelioma Interest Group | 1-gen-2005 | Porta, C.; Ardizzoni, A.; Gaudino, G.; Maio, M.; Mutti, L.; Pinto, C.; Porru, S.; Puntoni, R.; Tassi, G.; Tognon, M. | |
| Recurrent chromosome 6 abnormalities in malignant mesothelioma | 1-gen-1998 | Mutti, L. | |
| In vivo effect of human granulocyte-macrophage colony-stimulating factor (GM-CSF) on neutrophil GM-CSF receptors | 1-gen-1995 | Stacchini, A.; Fubini, L.; Gatti, E.; Mutti, L.; Piacibello, W.; Sanavio, F.; Scagliotti, G.; Pozzi, E.; Aglietta, M. | |
| Taurolidine and oxidative stress: A rationale for local treatment of mesothelioma | 1-gen-2009 | Aceto, N.; Bertino, P.; Barbone, D.; Tassi, G.; Manzo, L.; Porta, C.; Mutti, L.; Gaudino, G. | |
| New agents in the management of advanced mesothelioma | 1-gen-2005 | Vogelzang, N. J.; Porta, C.; Mutti, L. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista38803
- 2 Contributo in Volume2
Data di pubblicazione
- In corso di stampa29
- 2020 - 202610575
- 2010 - 201912538
- 2000 - 20098044
- 1990 - 19995281
- 1980 - 19892072
- 1970 - 1979262
- 1966 - 19694
Editore
- EDP Sciences2
- Eliseo Ranzi, Katharina Kohse-Höi...2
- Humana Press Inc.2
- Wiley Online Library2
- Brill1
- Cambridge University Press: 20111
- Edizioni dell'U.M.I.1
- Elsevier1
- GIOVANNI COSTA1
- IFIP1
Rivista
- PHYSICAL REVIEW LETTERS179
- PLOS ONE150
- IEEE TRANSACTIONS ON ELECTROMAGNE...141
- L'INDUSTRIA DELLE COSTRUZIONI140
- APPLIED SCIENCES137
- PHYSICAL REVIEW. B, CONDENSED MAT...135
- INTERNATIONAL JOURNAL OF MOLECULA...131
- SCIENTIFIC REPORTS125
- TRANSPLANTATION PROCEEDINGS118
- ENERGIES106
Serie
- METHODS IN MOLECULAR BIOLOGY2
Keyword
- Humans1211
- Female618
- Male577
- Adult341
- Italy311
- Middle Aged300
- Aged247
- COVID-19240
- Neurology (clinical)227
- Child212
Lingua
- eng27816
- ita5263
- fre99
- spa97
- ger42
- lat9
- pol7
- por6
- rus6
- enm5
Accesso al fulltext
- no fulltext27072
- open8259
- restricted2455
- reserved922
- partially open90
- mixed4
- embargoed3